Bio-Rad Laboratories, Inc.Class A
BIOBio-Rad Laboratories, Inc. Class A (BIO) is a global leader in life science research and clinical diagnostics. The company develops, manufactures, and markets a broad range of products, including reagents, instruments, and software, used in scientific research, healthcare, and clinical diagnostics. Bio-Rad is known for its contributions to immunology, genetics, and microbiology, supporting advancements in molecular biology and personalized medicine.
Company News
Global blood group typing market expected to grow from $2.4 billion in 2024 to $3.9 billion by 2030, driven by advancements in molecular technologies, increasing surgeries, and healthcare infrastructure expansion in emerging economies.
AppLovin, an adtech company, was added to the S&P 500 in September 2025 after significant growth driven by its Axon 2.0 AI software. While S&P 500 inclusion doesn't guarantee future performance, the company shows promising growth potential by expanding beyond mobile gaming into e-commerce and connected TV advertising.
The global sample preparation market is expected to grow at a CAGR of 6.4% by 2031, driven by technological advancements in specimen collection and preparation. The consumables segment and solid-phase extraction technique are expected to lead the market growth.
Palantir Technologies (PLTR) stock jumped over 13% on Monday after being added to the S&P 500 index. The company's AI platform has driven strong revenue growth and profitability, but its valuation appears high, leading analysts to suggest the stock may be overpriced.
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
